Dijous 11 de juny, el Dipòsit Digital no estarà operatiu de 15:00 a 17:00 h per tasques de manteniment. Disculpeu les molèsties.
El jueves 11 de Junio, el Dipòsit Digital no estará operativo de 15:00 a 17:00 h debido a tareas de mantenimiento. Disculpen las molestias.
Thursday, Jun 11th, the Digital Repository will be unavailable due to a system update.

Files

CamineroJA_Lancet_2019_Correspondence.pdf (66.23 KB)

Document type

Article

Version

Accepted version

Publication date

2019-07-27

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/140760

Multidrug-resistant tuberculosis

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

http://dx.doi.org/10.1016/S0140-6736(19)30696-8

Abstract

The ideal number of drugs needed and treatment duration are crucial issues in the management of multidrug-resistant tuberculosis (MDR-TB). Thus, we read with interest the Article by the Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017,1 the results of which support our proposal,2 from 2015, to classify anti-tuberculosis drugs on the basis of their toxicity, and sterilising or bactericidal activity.

Subject

Tuberculosi, Resistència als medicaments

Subject (English)

Tuberculosis, Drug resistance

Citation

Collections

Articles publicats en revistes (ISGlobal)

Citation

CAMINERO, José A ., GARCÍA-BASTEIRO, Alberto L. and RENDON, Adrian. Multidrug-resistant tuberculosis. The Lancet. 2019. Vol. 394, num. 10195, pags. 298. ISSN 0140-6736. [consulted: 10 of June of 2026]. Available at: https://hdl.handle.net/2445/140760

Export metadata

JSON - METS

Share record